A new trading day began on Monday, with Novavax, Inc. (NASDAQ: NVAX) stock price up 0.23% from the previous day of trading, before settling in for the closing price of $4.42. NVAX’s price has ranged from $3.53 to $11.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 513.29% over the last five years. Meanwhile, its annual earnings per share averaged 85.27%. With a float of $131.81 million, this company’s outstanding shares have now reached $139.51 million.
The firm has a total of 1543 workers. Let’s measure their productivity.
Novavax, Inc. (NVAX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Novavax, Inc. is 5.82%, while institutional ownership is 55.75%.
Novavax, Inc. (NVAX) Recent Fiscal highlights
In its latest quarterly report, released on 12/30/2023, the company reported earnings of -$1.44 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.27% per share during the next fiscal year.
Novavax, Inc. (NASDAQ: NVAX) Trading Performance Indicators
Here are Novavax, Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.54, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Novavax, Inc. (NVAX)
Analysing the last 5-days average volume posted by the [Novavax, Inc., NVAX], we can find that recorded value of 3.58 million was lower than the volume posted last year of 8.19 million. As of the previous 9 days, the stock’s Stochastic %D was 15.06%. Additionally, its Average True Range was 0.31.
During the past 100 days, Novavax, Inc.’s (NVAX) raw stochastic average was set at 30.15%, which indicates a significant increase from 13.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.44% in the past 14 days, which was lower than the 83.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.65, while its 200-day Moving Average is $6.25. Now, the first resistance to watch is $4.49. This is followed by the second major resistance level at $4.54. The third major resistance level sits at $4.61. If the price goes on to break the first support level at $4.37, it is likely to go to the next support level at $4.30. Now, if the price goes above the second support level, the third support stands at $4.25.
Novavax, Inc. (NASDAQ: NVAX) Key Stats
With a market capitalization of 619.98 million, the company has a total of 139,953K Shares Outstanding. Currently, annual sales are 983,710 K while annual income is -545,060 K. The company’s previous quarter sales were 291,340 K while its latest quarter income was -178,390 K.
